During the past decade, St. Francis Medical Institute conducted 41 clinical trials. In the 10-year time frame, 41 clinical trials started and 17 clinical trials were completed, i.e. on average, 41.5% percent of trials that started reached the finish line to date. In the past 5 years, 27 clinical trials started and 16 clinical trials were completed. i.e. 59.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "St. Francis Medical Institute" #1 sponsor was "United Therapeutics" with 6 trials, followed by "Eli Lilly and Company" with 3 trials sponsored, "Takeda" with 3 trials sponsored, "Boehringer Ingelheim" with 2 trials sponsored and "Eisai Inc." with 2 trials sponsored. Other sponsors include 24 different institutions and companies that sponsored additional 29 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "St. Francis Medical Institute" #1 collaborator was "Dermira, Inc." with 3 trials as a collaborator, "Lung Biotechnology PBC" with 2 trials as a collaborator, "Iqvia Pty Ltd" with 1 trials as a collaborator, "National Heart, Lung, and Blood Institute (NHLBI)" with 1 trials as a collaborator and "Pfizer" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "St. Francis Medical Institute" are "Idiopathic Pulmonary Fibrosis" (10 trials), "Chronic Obstructive Pulmonary Disease" (5 trials), "Pulmonary Hypertension" (5 trials), "Asthma" (4 trials) and "Atopic Dermatitis" (3 trials). Many other conditions were trialed in "St. Francis Medical Institute" in a lesser frequency.

Most popular intervention types in "St. Francis Medical Institute" are "Drug" (38 trials), "Other" (4 trials), "Biological" (3 trials), "Device" (2 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (29 trials), "Lebrikizumab" (4 trials), "Inhaled Treprostinil" (3 trials), "Daridorexant 25 mg" (2 trials) and "Daridorexant 50 mg" (2 trials). Other intervention names were less common.

The vast majority of trials in "St. Francis Medical Institute" are 45 trials for "All" genders.

Currently, there are NaN active trials in "St. Francis Medical Institute". undefined are not yet recruiting, 7 are recruiting, 5 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 25 completed trials in St. Francis Medical Institute, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in St. Francis Medical Institute, 3 "Phase 1" clinical trials were conducted, 16 "Phase 2" clinical trials and 22 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".